Sunho Biologics (HKSE:02898) Construction In Progress: HK$9.48 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02898 Sunho Biologics Inc HKSE:02898
11 GF Score
Price HK$6.39
! 1 Warning Sign
View Full Analysis

What is Sunho Biologics Construction In Progress?

Sunho Biologics HKSE:02898 11 Construction In Progress is HK$9.48 Mil as of Jun. 2025. GuruFocus rates HKSE:02898 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Sunho Biologics's quarterly construction in progress declined from Jun. 2024 (HK$4.45 Mil) to Dec. 2024 (HK$3.35 Mil) but then increased from Dec. 2024 (HK$3.35 Mil) to Jun. 2025 (HK$9.48 Mil).

Sunho Biologics's annual construction in progress declined from Dec. 2022 (HK$3.36 Mil) to Dec. 2023 (HK$1.26 Mil) but then increased from Dec. 2023 (HK$1.26 Mil) to Dec. 2024 (HK$3.35 Mil).

Sunho Biologics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sunho Biologics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunho Biologics Construction In Progress Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
Construction In Progress
3.36 1.26 3.35

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Construction In Progress Get a 7-Day Free Trial 0.00 1.26 4.45 3.35 9.48
HKSE:02898
11GF Score
Sunho Biologics Inc HKSE:02898
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunho Biologics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$9.48 Mil mean?
Sunho Biologics (HKSE:02898) has a Construction In Progress of HK$9.48 Mil as of Jun. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Sunho Biologics and its competitors.
Is Sunho Biologics' Construction In Progress too high?
Sunho Biologics' current Construction In Progress is HK$9.48 Mil. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' Construction In Progress compare to VRTX and REGN?
Sunho Biologics' Construction In Progress of HK$9.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sunho Biologics and its competitors. Sunho Biologics's current Construction In Progress is HK$9.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current Construction In Progress of HK$9.48 Mil. The current Construction In Progress is HK$9.48 Mil. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current Construction In Progress is HK$9.48 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunho Biologics Business Description

Address No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score

Get the complete analysis for HKSE:02898

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.39
Price